CoChat
Sign Up
Cited by 97Cancer Research and TreatmentsOral microbiology and periodontitis researchProbiotics and Fermented Foods

Promising dawn in tumor microenvironment therapy: engineering oral bacteria

Open access
Wang, Zifei, Sun, Wansu, Hua, Ruixue, Wang, Yuanyin, Li, Yang, Zhang, Hengguo·2024·International Journal of Oral Science
DOI 10.1038/s41368-024-00282-3PMC PMC10933493
Open this paper in CoChat — free accountOpen PDF

Abstract

Despite decades of research, cancer continues to be a major global health concern. The human mouth appears to be a multiplicity of local environments communicating with other organs and causing diseases via microbes. Nowadays, the role of oral microbes in the development and progression of cancer has received increasing scrutiny. At the same time, bioengineering technology and nanotechnology is growing rapidly, in which the physiological activities of natural bacteria are modified to improve the therapeutic efficiency of cancers. These engineered bacteria were transformed to achieve directed genetic reprogramming, selective functional reorganization and precise control. In contrast to endotoxins produced by typical genetically modified bacteria, oral flora exhibits favorable biosafety characteristics. To outline the current cognitions upon oral microbes, engineered microbes and human cancers, related literatures were searched and reviewed based on the PubMed database. We focused on a number of oral microbes and related mechanisms associated with the tumor microenvironment, which involve in cancer occurrence and development. Whether engineering oral bacteria can be a possible application of cancer therapy is worth consideration. A deeper understanding of the relationship between engineered oral bacteria and cancer therapy may enhance our knowledge of tumor pathogenesis thus providing new insights and strategies for cancer prevention and treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41368-024-00282-3

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Advances in synthetic biology allow phages to be engineered as programmable anticancer agents capable of remodeling the microbiome or delivering immunomodulatory payloads.

    “Advances in synthetic biology now allow phages to be engineered as programmable anticancer agents, capable of remodeling the microbiome or delivering immunomodulatory payloads [30–33]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [32]

    The Introduction and Therapeutic mechanisms section describe synthetic-biology engineering of bacteria to deliver anticancer agents and immunomodulatory payloads. They do not establish that phages can be engineered for these purposes or used to remodel the microbiome; searches for phages and microbiome remodeling found no supporting passage. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • Phages can deliver targeted therapeutic payloads.

    “Phages can eliminate cancer-associated bacteria, remodel the tumor microenvironment, enhance antitumor immunity, and deliver targeted therapeutic payloads.”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [32]

    The Fusobacterium sp. section describes the bacteriophage FNU1 as a possible way to eradicate tumor-associated bacteria, but does not describe it delivering therapeutic payloads. The Introduction and Gene-targeted bacterial therapy section attribute payload delivery to engineered bacteria, particularly Salmonella, not phages. Searches for phage-mediated payload delivery found no supporting passage; page numbers were unavailable in our copy. (LLM, conf=0.73)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 259

  1. [1]Sung H Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338 · DOI · Paper page
  2. [2]Tomasetti C Vogelstein B Variation in cancer risk among tissues can be explained by the number of stem cell divisions Science 2015 347 78 81 10.1126/science.1260825 25554788 PMC4446723 · DOI · Paper page
  3. [3]Whiteman DC Wilson LF The fractions of cancer attributable to modifiable factors: A global review Cancer Epidemiol. 2016 44 203 221 10.1016/j.canep.2016.06.013 27460784 · DOI
  4. [4]Lewandowska AM Rudzki M Rudzki S Lewandowski T Laskowska B Environmental risk factors for cancer - review paper Ann. Agric. Environ. Med.: AAEM 2019 26 1 7 10.26444/aaem/94299 30922021 · DOI
  5. [5]Liang K Liu Q Kong Q New technologies in developing recombinant-attenuated bacteria for cancer therapy Biotechnol. Bioeng. 2021 118 513 530 10.1002/bit.27596 33038015 · DOI
  6. [6]Demicheli R Retsky MW Hrushesky WJ Baum M Gukas ID The effects of surgery on tumor growth: a century of investigations Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. 2008 19 1821 1828 10.1093/annonc/mdn386 18550576 · DOI
  7. [7]Liu J Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer Bioact. Mater. 2024 31 315 332 37663619 PMC10468327
  8. [8]Diakos CI Charles KA McMillan DC Clarke SJ Cancer-related inflammation and treatment effectiveness Lancet Oncol. 2014 15 e493 e503 10.1016/S1470-2045(14)70263-3 25281468 · DOI · Paper page
  9. [9]Pointer KB Pitroda SP Weichselbaum RR Radiotherapy and immunotherapy: open questions and future strategies Trends cancer 2022 8 9 20 10.1016/j.trecan.2021.10.003 34740553 · DOI
  10. [10]Hu W Wang G Huang D Sui M Xu Y Cancer immunotherapy based on natural killer cells: current progress and new opportunities Front. Immunol. 2019 10 1205 10.3389/fimmu.2019.01205 31214177 PMC6554437 · DOI
  11. [11]Sun X Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy Nat. Nanotechnol. 2021 16 1260 1270 10.1038/s41565-021-00962-9 34594005 PMC8595610 · DOI
  12. [13]Duong MT Qin Y You SH Min JJ Bacteria-cancer interactions: bacteria-based cancer therapy Exp. Mol. Med. 2019 51 1 15 10.1038/s12276-019-0297-0 31827064 PMC6906302 · DOI
  13. [14]Siegall CB FitzGerald DJ Pastan I Selective killing of tumor cells using EGF or TGF alpha-Pseudomonas exotoxin chimeric molecules Semin. Cancer Biol. 1990 1 345 350 2129426
  14. [15]Jiang SN Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy Mol. Ther. J. Am. Soc. Gene Ther. 2010 18 635 642 10.1038/mt.2009.295 PMC2839435 20051939 · DOI
  15. [16]St Jean AT Swofford CA Panteli JT Brentzel ZJ Forbes NS Bacterial delivery of Staphylococcus aureus α-hemolysin causes regression and necrosis in murine tumors Mol. Ther. J. Am. Soc. Gene Ther. 2014 22 1266 1274 10.1038/mt.2014.36 PMC4089002 24590046 · DOI
  16. [17]Lehouritis P Springer C Tangney M Bacterial-directed enzyme prodrug therapy J. Control. Rel. 2013 170 120 131 10.1016/j.jconrel.2013.05.005 23688772 · DOI
  17. [18]Li Z Chemically and biologically engineered bacteria-based delivery systems for emerging diagnosis and advanced therapy Adv. Mater. 2021 33 e2102580 10.1002/adma.202102580 34347325 · DOI
  18. [21]Kilian M The oral microbiome - friend or foe? Eur. J. Oral. Sci. 2018 126 5 12 10.1111/eos.12527 30178561 · DOI
  19. [22]Zheng DW Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma Nat. Biomed. Eng. 2022 6 32 43 10.1038/s41551-021-00807-9 34750535 · DOI
  20. [23]Karpiński, T. M. Role of oral microbiota in cancer development. Microorganisms7, 10.3390/microorganisms7010020 (2019). PMC6352272 30642137 · DOI
  21. [24]Laugisch O Periodontal pathogens and associated intrathecal antibodies in early stages of Alzheimer’s disease J. Alzheimer’s Dis.: JAD 2018 66 105 114 10.3233/JAD-180620 30223397 · DOI
  22. [25]Mesa F Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives Biochim. Biophys. Mol. Basis Dis. 2019 1865 476 484 10.1016/j.bbadis.2018.12.001 30529255 · DOI
  23. [26]Whitmore SE Lamont RJ Oral bacteria and cancer PLoS Pathog. 2014 10 e1003933 10.1371/journal.ppat.1003933 24676390 PMC3968118 · DOI
  24. [29]Katz J Onate MD Pauley KM Bhattacharyya I Cha S Presence of Porphyromonas gingivalis in gingival squamous cell carcinoma Int. J. Oral. Sci. 2011 3 209 215 10.4248/IJOS11075 22010579 PMC3469978 · DOI
  25. [30]Structure, function and diversity of the healthy human microbiome. Nature486, 207–214, (2012). PMC3564958 22699609
  26. [31]Gurbatri CR Arpaia N Danino T Engineering bacteria as interactive cancer therapies Science 2022 378 858 864 10.1126/science.add9667 36423303 PMC10584033 · DOI
  27. [32]Fan JX Niu MT Qin YT Sun YX Zhang XZ Progress of engineered bacteria for tumor therapy Adv. Drug Deliv. Rev. 2022 185 114296 10.1016/j.addr.2022.114296 35439571 · DOI
  28. [33]Wade WG The oral microbiome in health and disease Pharmacol. Res. 2013 69 137 143 10.1016/j.phrs.2012.11.006 23201354 · DOI · Paper page
  29. [35]Chatzigiannidou I Teughels W Van de Wiele T Boon N Oral biofilms exposure to chlorhexidine results in altered microbial composition and metabolic profile NPJ Biofilms Microbiomes 2020 6 13 10.1038/s41522-020-0124-3 32198347 PMC7083908 · DOI
  30. [36]Simón-Soro A Microbial geography of the oral cavity J. Dent. Res. 2013 92 616 621 10.1177/0022034513488119 23674263 · DOI
  31. [37]Zijnge V Oral biofilm architecture on natural teeth PloS One 2010 5 e9321 10.1371/journal.pone.0009321 20195365 PMC2827546 · DOI
  32. [38]Minamino T Imada K The bacterial flagellar motor and its structural diversity Trends Microbiol. 2015 23 267 274 10.1016/j.tim.2014.12.011 25613993 · DOI
  33. [39]Sowa Y Direct observation of steps in rotation of the bacterial flagellar motor Nature 2005 437 916 919 10.1038/nature04003 16208378 · DOI
  34. [40]Kinosita Y Uchida N Nakane D Nishizaka T Direct observation of rotation and steps of the archaellum in the swimming halophilic archaeon Halobacterium salinarum Nat. Microbiol. 2016 1 16148 10.1038/nmicrobiol.2016.148 27564999 · DOI
  35. [41]Kearns DB A field guide to bacterial swarming motility Nat. Rev. Microbiol. 2010 8 634 644 10.1038/nrmicro2405 20694026 PMC3135019 · DOI · Paper page
  36. [42]Zhang Y E. coli Nissle 1917-Derived Minicells For Targeted Delivery Of Chemotherapeutic Drug To Hypoxic Regions For Cancer Therapy Theranostics 2018 8 1690 1705 10.7150/thno.21575 29556350 PMC5858176 · DOI
  37. [43]Chien T Enhancing the tropism of bacteria via genetically programmed biosensors Nat. Biomed. Eng. 2022 6 94 104 10.1038/s41551-021-00772-3 34326488 PMC8956018 · DOI
  38. [44]Flentie K A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy Cancer Discov. 2012 2 624 637 10.1158/2159-8290.CD-11-0201 22728436 PMC3395769 · DOI
  39. [45]Sharma A Hypoxia-targeted drug delivery Chem. Soc. Rev. 2019 48 771 813 10.1039/C8CS00304A 30575832 PMC6361706 · DOI
  40. [46]Zou W Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat. Rev. Cancer 2005 5 263 274 10.1038/nrc1586 15776005 · DOI · Paper page
  41. [47]Huang N Gold nanoparticles induce tumor vessel normalization and impair metastasis by inhibiting Endothelial Smad2/3 signaling ACS Nano 2020 14 7940 7958 10.1021/acsnano.9b08460 32413258 · DOI
  42. [48]Yang S Tumor temporal proteome profiling reveals the immunological triple offensive induced by synthetic anti-cancer Salmonella Front. Immunol. 2021 12 712936 10.3389/fimmu.2021.712936 34489962 PMC8417115 · DOI
  43. [49]Forbes NS White paper on microbial anti-cancer therapy and prevention J. Immunother. Cancer 2018 6 78 10.1186/s40425-018-0381-3 30081947 PMC6091193 · DOI
  44. [50]Kasinskas RW Forbes NS Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis Cancer Res. 2007 67 3201 3209 10.1158/0008-5472.CAN-06-2618 17409428 · DOI
  45. [51]Ho CL Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention Nat. Biomed. Eng. 2018 2 27 37 10.1038/s41551-017-0181-y 31015663 · DOI · Paper page
  46. [52]He L Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy J. Biol. Eng. 2019 13 58 10.1186/s13036-019-0189-9 31297149 PMC6599283 · DOI
  47. [53]Jiang SN Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent Mol. Ther. J. Am. Soc. Gene Ther. 2013 21 1985 1995 10.1038/mt.2013.183 PMC3831040 23922014 · DOI
  48. [54]Zheng, J. H. et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci. Transl. Med.9, 10.1126/scitranslmed.aak9537 (2017). 28179508 · DOI · Paper page
  49. [55]Ramesh G MacLean AG Philipp MT Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain Mediat. Inflamm. 2013 2013 480739 10.1155/2013/480739 PMC3753746 23997430 · DOI · Paper page
  50. [56]Sorenson BS Banton KL Frykman NL Leonard AS Saltzman DA Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma Clin. Orthop. Relat. Res. 2008 466 1285 1291 10.1007/s11999-008-0243-2 18421536 PMC2384016 · DOI
  51. [57]Zhang HY Tumor-targeted delivery of biologically active TRAIL protein Cancer Gene Ther. 2010 17 334 343 10.1038/cgt.2009.76 20075981 PMC2859322 · DOI
  52. [58]Hosseini-Giv N Bahrami AR Matin MM Application of bacterial directed enzyme prodrug therapy as a targeted chemotherapy approach in a mouse model of breast cancer Int. J. Pharm. 2021 606 120931 10.1016/j.ijpharm.2021.120931 34310961 · DOI
  53. [59]Sharrock AV Engineering the Escherichia coli Nitroreductase NfsA to create a flexible enzyme-prodrug activation system Front. Pharmacol. 2021 12 701456 10.3389/fphar.2021.701456 34163368 PMC8215503 · DOI
  54. [60]Chen W Bacteria-driven hypoxia targeting for combined biotherapy and photothermal therapy ACS nano 2018 12 5995 6005 10.1021/acsnano.8b02235 29786420 · DOI
  55. [61]Yang Z Engineering bioluminescent bacteria to boost photodynamic therapy and systemic anti-tumor immunity for synergistic cancer treatment Biomaterials 2022 281 121332 10.1016/j.biomaterials.2021.121332 35066286 · DOI
  56. [62]Kim SH Castro F Paterson Y Gravekamp C High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action Cancer Res. 2009 69 5860 5866 10.1158/0008-5472.CAN-08-4855 19584282 PMC3127451 · DOI
  57. [63]Liu Y Intravenous delivery of living listeria monocytogenes elicits gasdmermin-dependent tumor pyroptosis and motivates anti-tumor immune response ACS Nano 2022 16 4102 4115 10.1021/acsnano.1c09818 35262333 · DOI
  58. [64]Liu Y Bacterial-mediated tumor therapy: old treatment in a new context Adv. Sci. 2023 10 e2205641 10.1002/advs.202205641 PMC10131876 36908053 · DOI
  59. [65]Fan JX Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α Expression via oral administration Nano Lett. 2018 18 2373 2380 10.1021/acs.nanolett.7b05323 29558152 · DOI
  60. [66]Ptacin JL An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism Nat. Commun. 2021 12 4785 10.1038/s41467-021-24987-9 34373459 PMC8352909 · DOI
  61. [67]Tanoue T A defined commensal consortium elicits CD8 T cells and anti-cancer immunity Nature 2019 565 600 605 10.1038/s41586-019-0878-z 30675064 · DOI · Paper page
  62. [68]Zhang Y Synergistic cancer immunotherapy utilizing programmed Salmonella typhimurium secreting heterologous flagellin B conjugated to interleukin-15 proteins Biomaterials 2023 298 122135 10.1016/j.biomaterials.2023.122135 37148758 · DOI
  63. [69]Gurbatri, C. R. et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med.12, 10.1126/scitranslmed.aax0876 (2020). PMC7685004 32051224 · DOI · Paper page
  64. [70]Chowdhury S Programmable bacteria induce durable tumor regression and systemic antitumor immunity Nat. Med. 2019 25 1057 1063 10.1038/s41591-019-0498-z 31270504 PMC6688650 · DOI · Paper page
  65. [71]Lin Z In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity Bioact. Mater. 2024 32 12 27 37790917 PMC10542607
  66. [72]Yoon W Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma Eur. J. Cancer 2017 70 48 61 10.1016/j.ejca.2016.10.010 27883926 · DOI
  67. [73]Peek MC Systematic review of high-intensity focused ultrasound ablation in the treatment of breast cancer Br. J. Surg. 2015 102 873 882 10.1002/bjs.9793 26095255 · DOI
  68. [74]Um W Necroptosis-inducible polymeric nanobubbles for enhanced cancer sonoimmunotherapy Adv. Mater. 2020 32 e1907953 10.1002/adma.201907953 32125731 · DOI
  69. [75]Devarakonda SB Myers MR Lanier M Dumoulin C Banerjee RK Assessment of gold nanoparticle-mediated-enhanced hyperthermia using MR-guided high-intensity focused ultrasound ablation procedure Nano Lett. 2017 17 2532 2538 10.1021/acs.nanolett.7b00272 28287747 · DOI
  70. [76]Liang X Nanohybrid liposomal cerasomes with good physiological stability and rapid temperature responsiveness for high intensity focused ultrasound triggered local chemotherapy of cancer ACS Nano 2015 9 1280 1293 10.1021/nn507482w 25599568 · DOI
  71. [77]Chen Y Du M Yuan Z Chen Z Yan F Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy Nat. Commun. 2022 13 4468 10.1038/s41467-022-31932-x 35918309 PMC9345953 · DOI
  72. [78]Abedi MH Ultrasound-controllable engineered bacteria for cancer immunotherapy Nat. Commun. 2022 13 1585 10.1038/s41467-022-29065-2 35332124 PMC8948203 · DOI
  73. [80]Felfoul O Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions Nat. Nanotechnol. 2016 11 941 947 10.1038/nnano.2016.137 27525475 PMC6094936 · DOI
  74. [81]Ray PD Huang BW Tsuji Y Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling Cell. Signal. 2012 24 981 990 10.1016/j.cellsig.2012.01.008 22286106 PMC3454471 · DOI · Paper page
  75. [82]Kumari S Badana AK Murali GM Shailender G Malla R Reactive oxygen species: a key constituent in cancer survival Biomark. insights 2018 13 1177271918755391 10.1177/1177271918755391 29449774 PMC5808965 · DOI
  76. [83]Cui Q Modulating ROS to overcome multidrug resistance in cancer Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 2018 41 1 25 10.1016/j.drup.2018.11.001 30471641 · DOI
  77. [84]Yang B Light-activatable dual-source ROS-responsive prodrug nanoplatform for synergistic chemo-photodynamic therapy Biomater. Sci. 2018 6 2965 2975 10.1039/C8BM00899J 30255178 · DOI
  78. [85]Guo Y Photodynamic therapy-improved oncolytic bacterial immunotherapy with FAP-encoding S. typhimurium J. Control. Rel. 2022 351 860 871 10.1016/j.jconrel.2022.09.050 36181917 · DOI
  79. [86]Yaqoob MD Xu L Li C Leong MML Xu DD Targeting mitochondria for cancer photodynamic therapy Photodiag. Photodyn. Ther. 2022 38 102830 10.1016/j.pdpdt.2022.102830 35341979 · DOI
  80. [87]Zaloga GP Parenteral nutrition in adult inpatients with functioning gastrointestinal tracts: assessment of outcomes Lancet 2006 367 1101 1111 10.1016/S0140-6736(06)68307-4 16581410 · DOI
  81. [88]Górska A Przystupski D Niemczura MJ Kulbacka J Probiotic bacteria: a promising tool in cancer prevention and therapy Curr. Microbiol. 2019 76 939 949 10.1007/s00284-019-01679-8 30949803 PMC6586914 · DOI · Paper page
  82. [89]Yue T Antitumor effect of invasive Lactobacillus plantarum delivering associated antigen gene sHSP between Trichinella spiralis and Lewis lung cancer cells Int. Immunopharmacol. 2023 115 109708 10.1016/j.intimp.2023.109708 36638662 · DOI
  83. [90]Kitagawa K An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model Mol. Ther. Oncolytics 2021 22 592 603 10.1016/j.omto.2021.08.009 34589578 PMC8449024 · DOI
  84. [91]Zhou, H. et al. Intravenous Administration Is an Effective and Safe Route for Cancer Gene Therapy Using the Bifidobacterium-Mediated Recombinant HSV-1 Thymidine Kinase and Ganciclovir. International journal of molecular sciences17, 10.3390/ijms17060891 (2016). PMC4926425 27275821 · DOI
  85. [92]Xiong S Attenuated Salmonella typhimurium-mediated tumour targeting imaging based on peptides Biomater. Sci. 2020 8 3712 3719 10.1039/D0BM00013B 32495762 · DOI
  86. [93]Melero I Castanon E Alvarez M Champiat S Marabelle A Intratumoural administration and tumour tissue targeting of cancer immunotherapies Nat. Rev. Clin. Oncol. 2021 18 558 576 10.1038/s41571-021-00507-y 34006998 PMC8130796 · DOI
  87. [94]McCarthy EF The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas IOWA Orthop. J. 2006 26 154 158 16789469 PMC1888599
  88. [96]Pan H Zheng M Ma A Liu L Cai L Cell/Bacteria-based bioactive materials for cancer immune modulation and precision therapy Adv. Mater. 2021 33 e2100241 10.1002/adma.202100241 34121236 · DOI
  89. [97]Dróżdż M Makuch S Cieniuch G Woźniak M Ziółkowski P Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications Life Sci. 2020 261 118296 10.1016/j.lfs.2020.118296 32822716 · DOI
  90. [99]Darvin P Toor SM Sasidharan Nair V Elkord E Immune checkpoint inhibitors: recent progress and potential biomarkers Exp. Mol. Med. 2018 50 1 11 10.1038/s12276-018-0191-1 30546008 PMC6292890 · DOI · Paper page
  91. [101]Wang SJ Dougan SK Dougan M Immune mechanisms of toxicity from checkpoint inhibitors Trends cancer 2023 9 543 553 10.1016/j.trecan.2023.04.002 37117135 PMC10330206 · DOI
  92. [104]Naciute M Kiwitt T Kemp RA Hook S Bacteria biohybrid oral vaccines for colorectal cancer treatment reduce tumor growth and increase immune infiltration Vaccine 2021 39 5589 5599 10.1016/j.vaccine.2021.08.028 34419301 · DOI
  93. [105]Murakami T Tumor-targeting Salmonella typhimurium A1-R promotes Tumoricidal CD8(+) T cell tumor infiltration and arrests growth and metastasis in a syngeneic pancreatic-cancer orthotopic mouse model J. Cell. Biochem. 2018 119 634 639 10.1002/jcb.26224 28628234 · DOI
  94. [106]Thornlow DN Brackett EL Gigas JM Van Dessel N Forbes NS Persistent enhancement of bacterial motility increases tumor penetration Biotechnol. Bioeng. 2015 112 2397 2405 10.1002/bit.25645 25976712 PMC4586311 · DOI
  95. [107]Guallar-Garrido S Julián E Bacillus Calmette-Guérin (BCG) therapy for bladder cancer: an update ImmunoTargets Ther. 2020 9 1 11 10.2147/ITT.S202006 32104666 PMC7025668 · DOI
  96. [108]Lin, S. et al. Mucosal immunity-mediated modulation of the gut microbiome by oral delivery of probiotics into Peyer’s patches. Science advances7, 10.1126/sciadv.abf0677 (2021). PMC8115924 33980483 · DOI
  97. [109]Nguyen PQ Courchesne ND Duraj-Thatte A Praveschotinunt P Joshi NS Engineered living materials: prospects and challenges for using biological systems to direct the assembly of smart materials Adv. Mater. 2018 30 e1704847 10.1002/adma.201704847 29430725 PMC6309613 · DOI
  98. [110]Mi Z “Trojan Horse” Salmonella Enabling Tumor homing of silver nanoparticles via neutrophil infiltration for synergistic tumor therapy and enhanced biosafety Nano Lett. 2021 21 414 423 10.1021/acs.nanolett.0c03811 33356313 · DOI
  99. [111]Pangilinan, C. R. & Lee, C. H. Salmonella-based targeted cancer therapy: updates on a promising and innovative tumor immunotherapeutic strategy. Biomedicines7, 10.3390/biomedicines7020036 (2019). PMC6630963 31052558 · DOI
  100. [112]Liu X Metabolically engineered bacteria as light-controlled living therapeutics for anti-angiogenesis tumor therapy Mater. Horiz. 2021 8 1454 1460 10.1039/D0MH01582B 34846453 · DOI
  101. [113]Liu J Sun X Advances in bacteria-based therapy for drug delivery Adv. drug Deliv. Rev. 2022 190 114565 10.1016/j.addr.2022.114565 36174790 · DOI
  102. [114]Wu F Liu J Decorated bacteria and the application in drug delivery Adv. drug Deliv. Rev. 2022 188 114443 10.1016/j.addr.2022.114443 35817214 · DOI
  103. [115]Yoo JW Irvine DJ Discher DE Mitragotri S Bio-inspired, bioengineered and biomimetic drug delivery carriers Nat. Rev. Drug Discov. 2011 10 521 535 10.1038/nrd3499 21720407 · DOI
  104. [116]Song WF Zheng D Zeng SM Zeng X Zhang XZ Targeting to tumor-harbored bacteria for precision tumor therapy ACS Nano 2022 16 17402 17413 10.1021/acsnano.2c08555 36200710 · DOI
  105. [117]Zhan Y Improved tumor infiltration and immunomodulation for tumor therapy: a pathway based on tetrahedral framework nucleic acids coupled bacterial nanocells Nano Lett. 2023 23 353 362 10.1021/acs.nanolett.2c03943 36394269 · DOI
  106. [118]Cao Z Liu J Bacteria and bacterial derivatives as drug carriers for cancer therapy J. Control. Rel. 2020 326 396 407 10.1016/j.jconrel.2020.07.009 32681947 · DOI
  107. [119]Xie S Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release J. Control. Rel. 2017 268 390 399 10.1016/j.jconrel.2017.10.041 29101053 · DOI
  108. [120]Park BW Zhuang J Yasa O Sitti M Multifunctional bacteria-driven microswimmers for targeted active drug delivery ACS Nano 2017 11 8910 8923 10.1021/acsnano.7b03207 28873304 · DOI
  109. [121]Alapan, Y. et al. Soft erythrocyte-based bacterial microswimmers for cargo delivery. Sci. Robot.3, 10.1126/scirobotics.aar4423 (2018). 33141741 · DOI
  110. [122]Barbé S Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment FEMS Microbiol. Lett. 2005 246 67 73 10.1016/j.femsle.2005.03.037 15869963 · DOI
  111. [123]Chen W Zhu Y Zhang Z Sun X Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy Adv. Drug Deliv. Rev. 2022 185 114295 10.1016/j.addr.2022.114295 35429576 · DOI
  112. [124]Beutler B Rietschel ET Innate immune sensing and its roots: the story of endotoxin Nat. Rev. Immunol. 2003 3 169 176 10.1038/nri1004 12563300 · DOI
  113. [125]Low KB Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo Nat. Biotechnol. 1999 17 37 41 10.1038/5205 9920266 · DOI
  114. [126]Ryan RM Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors Gene Ther. 2009 16 329 339 10.1038/gt.2008.188 19177133 · DOI
  115. [127]Nguyen VH Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer Cancer Res. 2010 70 18 23 10.1158/0008-5472.CAN-09-3453 20028866 · DOI
  116. [128]Yu B Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella Typhimurium strain Sci. Rep. 2012 2 436 10.1038/srep00436 22666539 PMC3365283 · DOI
  117. [129]Chen P siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma Int. Immunopharmacol. 2022 111 109127 10.1016/j.intimp.2022.109127 35964407 · DOI
  118. [130]Tian Y Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC Cancer gene Ther. 2012 19 393 401 10.1038/cgt.2012.12 22555509 PMC3891655 · DOI
  119. [131]Raman V Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases Nat. Commun. 2021 12 6116 10.1038/s41467-021-26367-9 34675204 PMC8531320 · DOI
  120. [132]Liang K Optimized attenuated Salmonella Typhimurium suppressed tumor growth and improved survival in mice Front. Microbiol. 2021 12 774490 10.3389/fmicb.2021.774490 35003007 PMC8733734 · DOI
  121. [133]Aggarwal N Breedon AME Davis CM Hwang IY Chang MW Engineering probiotics for therapeutic applications: recent examples and translational outlook Curr. Opin. Biotechnol. 2020 65 171 179 10.1016/j.copbio.2020.02.016 32304955 · DOI
  122. [135]Hassan R Clinical response of live-attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma Clin. Cancer Res. 2019 25 5787 5798 10.1158/1078-0432.CCR-19-0070 31263030 PMC8132300 · DOI
  123. [136]Toso JF Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma J. Clin. Oncol. 2002 20 142 152 10.1200/JCO.2002.20.1.142 11773163 PMC2064865 · DOI
  124. [137]Lamm DL Morales A A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment Vaccine 2021 39 7308 7318 10.1016/j.vaccine.2021.08.026 34417051 · DOI
  125. [138]Wang J Maniruzzaman M A global bibliometric and visualized analysis of bacteria-mediated cancer therapy Drug Discov. Today 2022 27 103297 10.1016/j.drudis.2022.05.023 35654388 PMC9530009 · DOI
  126. [139]Saltzman DA Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent Cancer Biother. Radiopharm. 1996 11 145 153 10851531
  127. [141]Song S Vuai MS Zhong M The role of bacteria in cancer therapy - enemies in the past, but allies at present Infect. Agents Cancer 2018 13 9 10.1186/s13027-018-0180-y PMC5856380 29568324 · DOI
  128. [142]Lee YC Association Between Helicobacter Pylori Eradication And Gastric Cancer Incidence: A Systematic Review And Meta-analysis Gastroenterology 2016 150 1113 1124.e1115 10.1053/j.gastro.2016.01.028 26836587 · DOI
  129. [143]Clairmont C Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium J. Infect. Dis. 2000 181 1996 2002 10.1086/315497 10837181 · DOI
  130. [144]Hwang J An EK Kim SJ Zhang W Jin JO Escherichia coli Mimetic gold nanorod-mediated photo- and immunotherapy for treating cancer and its metastasis ACS Nano 2022 16 8472 8483 10.1021/acsnano.2c03379 35466668 · DOI
  131. [145]Caselli E Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture BMC Microbiol. 2020 20 120 10.1186/s12866-020-01801-y 32423437 PMC7236360 · DOI
  132. [146]Freire M Nelson KE Edlund A The oral host-microbial interactome: An ecological chronometer of health? Trends Microbiol. 2021 29 551 561 10.1016/j.tim.2020.11.004 33279381 · DOI
  133. [148]Desai S Fusobacterium nucleatum is associated with inflammation and poor survival in early-stage HPV-negative tongue cancer NAR cancer 2022 4 zcac006 10.1093/narcan/zcac006 35252868 PMC8894079 · DOI
  134. [149]Costa, C. P. D. et al. The tissue-associated microbiota in colorectal cancer: a systematic review. Cancers14, 10.3390/cancers14143385 (2022). PMC9317273 35884445 · DOI
  135. [150]Mäkinen AI Salivary microbiome profiles of oral cancer patients analyzed before and after treatment Microbiome 2023 11 171 10.1186/s40168-023-01613-y 37542310 PMC10403937 · DOI
  136. [151]Guo S A simple and novel fecal biomarker for colorectal cancer: ratio of Fusobacterium Nucleatum to probiotics populations, based on their antagonistic effect Clin. Chem. 2018 64 1327 1337 10.1373/clinchem.2018.289728 29914865 · DOI
  137. [152]Chen WD Fusobacterium nucleatum is a risk factor for metastatic colorectal cancer Curr. Med. Sci. 2022 42 538 547 10.1007/s11596-022-2597-1 35678912 · DOI
  138. [153]Zhang X Salivary Fusobacterium nucleatum serves as a potential biomarker for colorectal cancer iScience 2022 25 104203 10.1016/j.isci.2022.104203 35479401 PMC9035728 · DOI
  139. [155]Banerjee S Prognostic correlations with the microbiome of breast cancer subtypes Cell Death Dis. 2021 12 831 10.1038/s41419-021-04092-x 34482363 PMC8418604 · DOI
  140. [156]Tzeng A Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer Genome Med. 2021 13 60 10.1186/s13073-021-00874-2 33863341 PMC8052771 · DOI
  141. [157]Parhi L Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression Nat. Commun. 2020 11 3259 10.1038/s41467-020-16967-2 32591509 PMC7320135 · DOI · Paper page
  142. [158]Chen, G. et al. Fusobacterium nucleatum outer membrane vesicles activate autophagy to promote oral cancer metastasis. J. Adv. Res.10.1016/j.jare.2023.04.002 (2023). PMC10834801 37059221 · DOI
  143. [159]Casasanta, M. A. et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci. Signal.13, 10.1126/scisignal.aba9157 (2020). PMC7454160 32694172 · DOI
  144. [160]Chen S Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7 Gut Microbes 2020 11 511 525 10.1080/19490976.2019.1695494 31910722 PMC7524269 · DOI
  145. [161]Zare, A. et al. RIPK2: New elements in modulating inflammatory breast cancer pathogenesis. Cancers10, 10.3390/cancers10060184 (2018). PMC6025367 29874851 · DOI
  146. [162]Chen Y Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 Expression Theranostics 2020 10 323 339 10.7150/thno.38870 31903123 PMC6929621 · DOI
  147. [163]Yang Y Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of MicroRNA-21 Gastroenterology 2017 152 851 866.e824 10.1053/j.gastro.2016.11.018 27876571 PMC5555435 · DOI
  148. [164]Kong X Fusobacterium nucleatum-triggered neutrophil extracellular traps facilitate colorectal carcinoma progression J. Exp. Clin. Cancer Res.: CR 2023 42 236 10.1186/s13046-023-02817-8 37684625 PMC10492297 · DOI
  149. [165]Fatma H Maurya SK Siddique HR Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance Semin. cancer Biol. 2022 83 166 176 10.1016/j.semcancer.2020.11.008 33220458 · DOI
  150. [166]Iida N Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment Science 2013 342 967 970 10.1126/science.1240527 24264989 PMC6709532 · DOI · Paper page
  151. [167]Viaud S The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide Science 2013 342 971 976 10.1126/science.1240537 24264990 PMC4048947 · DOI · Paper page
  152. [168]Little A Tangney M Tunney MM Buckley NE Fusobacterium nucleatum: a novel immune modulator in breast cancer Expert Rev. Mol. Med. 2023 25 e15 10.1017/erm.2023.9 37009688 PMC10407221 · DOI
  153. [169]Despins CA Modulation of the host cell transcriptome and epigenome by Fusobacterium nucleatum mBio 2021 12 e0206221 10.1128/mBio.02062-21 34700376 PMC8546542 · DOI
  154. [170]Nawab, S. et al. The pathogenicity of fusobacterium nucleatum modulated by dietary fibers-a possible missing link between the dietary composition and the risk of colorectal cancer. Microorganisms11, 10.3390/microorganisms11082004 (2023). PMC10458976 37630564 · DOI
  155. [171]Yao Y Shen X Zhou M Tang B Periodontal pathogens promote oral squamous cell carcinoma by regulating ATR and NLRP3 inflammasome Front. Oncol. 2021 11 722797 10.3389/fonc.2021.722797 34660289 PMC8514820 · DOI
  156. [172]Udayasuryan B Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling Sci. Signal. 2022 15 eabn4948 10.1126/scisignal.abn4948 36256708 PMC9732933 · DOI
  157. [174]Jiang SS Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer Cell Host Microbe 2023 31 781 797.e789 10.1016/j.chom.2023.04.010 37130518 · DOI
  158. [176]Gao Y Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer Signal Transduct. Target. Ther. 2021 6 398 10.1038/s41392-021-00795-x 34795206 PMC8602417 · DOI
  159. [177]Li X Zhang S Guo G Han J Yu J Gut microbiome in modulating immune checkpoint inhibitors EBioMedicine 2022 82 104163 10.1016/j.ebiom.2022.104163 35841869 PMC9297075 · DOI
  160. [178]Kabwe M Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting Fusobacterium nucleatum biofilms Sci. Rep. 2019 9 9107 10.1038/s41598-019-45549-6 31235721 PMC6591296 · DOI
  161. [179]Hajishengallis G Abe T Maekawa T Hajishengallis E Lambris JD Role of complement in host-microbe homeostasis of the periodontium Semin. Immunol. 2013 25 65 72 10.1016/j.smim.2013.04.004 23684627 PMC3706506 · DOI
  162. [180]Ahn J Segers S Hayes RB Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality Carcinogenesis 2012 33 1055 1058 10.1093/carcin/bgs112 22367402 PMC3334514 · DOI
  163. [181]Irfan M Delgado RZR Frias-Lopez J The Oral Microbiome And Cancer Front. Immunol. 2020 11 591088 10.3389/fimmu.2020.591088 33193429 PMC7645040 · DOI · Paper page
  164. [182]Peters BA Oral microbiome composition reflects prospective risk for esophageal cancers Cancer Res. 2017 77 6777 6787 10.1158/0008-5472.CAN-17-1296 29196415 PMC5726431 · DOI · Paper page
  165. [183]Gao S Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer Infect. Agents Cancer 2016 11 3 10.1186/s13027-016-0049-x PMC4717526 26788120 · DOI
  166. [184]Chen X Predictive value of the presence of Prevotella and the ratio of Porphyromonas gingivalis to Prevotella in saliva for esophageal squamous cell carcinoma Front. Cell. Infect. Microbiol. 2022 12 997333 10.3389/fcimb.2022.997333 36310858 PMC9612942 · DOI
  167. [185]Guo ZC Jing SL Jumatai S Gong ZC Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment Cancer Immunol., Immunother. 2023 72 1523 1539 10.1007/s00262-022-03348-5 36513851 PMC10992093 · DOI
  168. [186]Kerdreux M Porphyromonas gingivalis in Colorectal Cancer And Its Association To Patient Prognosis J. Cancer 2023 14 1479 1485 10.7150/jca.83395 37325051 PMC10266249 · DOI
  169. [187]Groeger S PD-L1 up-regulation in prostate cancer cells by Porphyromonas gingivalis Front. Cell. Infect. Microbiol. 2022 12 935806 10.3389/fcimb.2022.935806 35846769 PMC9277116 · DOI
  170. [188]Tan Q Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils Gut Microbes 2022 14 2073785 10.1080/19490976.2022.2073785 35549648 PMC9116393 · DOI
  171. [189]Lamont RJ Fitzsimonds ZR Wang H Gao S Role of Porphyromonas gingivalis in oral and orodigestive squamous cell carcinoma Periodontology 2000 2022 89 154 165 10.1111/prd.12425 35244980 PMC9439709 · DOI
  172. [190]Yamada C Inhibitory effect of Porphyromonas gingivalis-derived phosphoethanolamine dihydroceramide on acid ceramidase expression in oral squamous cells J. Cell. Mol. Med. 2023 27 1290 1295 10.1111/jcmm.17722 37016912 PMC10148054 · DOI
  173. [191]Lamouille S Xu J Derynck R Molecular mechanisms of epithelial-mesenchymal transition Nat. Rev. Mol. cell Biol. 2014 15 178 196 10.1038/nrm3758 24556840 PMC4240281 · DOI · Paper page
  174. [192]Vandewalle C Van Roy F Berx G The role of the ZEB family of transcription factors in development and disease Cell. Mol. Life Sci. 2009 66 773 787 10.1007/s00018-008-8465-8 19011757 PMC11131515 · DOI
  175. [193]Ohshima J Streptococcus gordonii programs epithelial cells to resist ZEB2 induction by Porphyromonas gingivalis Proc. Natl Acad. Sci. USA 2019 116 8544 8553 10.1073/pnas.1900101116 30971493 PMC6486779 · DOI
  176. [194]Sztukowska MN Porphyromonas gingivalis initiates a mesenchymal-like transition through ZEB1 in gingival epithelial cells Cell. Microbiol. 2016 18 844 858 10.1111/cmi.12554 26639759 PMC5135094 · DOI
  177. [195]Rajendran P The multifaceted link between inflammation and human diseases J. Cell. Physiol. 2018 233 6458 6471 10.1002/jcp.26479 29323719 PMC13482531 · DOI
  178. [196]Hajishengallis G Lamont RJ Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology Mol. Oral. Microbiol. 2012 27 409 419 10.1111/j.2041-1014.2012.00663.x 23134607 PMC3653317 · DOI · Paper page
  179. [197]Hajishengallis G Lamont RJ Breaking bad: manipulation of the host response by Porphyromonas gingivalis Eur. J. Immunol. 2014 44 328 338 10.1002/eji.201344202 24338806 PMC3925422 · DOI
  180. [198]Yee M Kim S Sethi P Düzgüneş N Konopka K Porphyromonas gingivalis stimulates IL-6 and IL-8 secretion in GMSM-K, HSC-3 and H413 oral epithelial cells Anaerobe 2014 28 62 67 10.1016/j.anaerobe.2014.05.011 24887636 · DOI
  181. [199]Sahingur SE Yeudall WA Chemokine function in periodontal disease and oral cavity cancer Front. Immunol. 2015 6 214 10.3389/fimmu.2015.00214 25999952 PMC4419853 · DOI
  182. [200]Hu X Li J Fu M Zhao X Wang W The JAK/STAT signaling pathway: from bench to clinic Signal Transduct. Target. Ther. 2021 6 402 10.1038/s41392-021-00791-1 34824210 PMC8617206 · DOI · Paper page
  183. [201]Lü L JAK3 restrains inflammatory responses and protects against periodontal disease through Wnt3a signaling FASEB J. 2020 34 9120 9140 10.1096/fj.201902697RR 32433819 PMC7501269 · DOI
  184. [202]Meng F Porphyromonas gingivalis promotes the motility of esophageal squamous cell carcinoma by activating NF-κB signaling pathway Microbes Infect. 2019 21 296 304 10.1016/j.micinf.2019.01.005 30763763 · DOI
  185. [203]Jia X Liu J He Y Huang X Porphyromonas gingivalis secretion leads to dysplasia of normal esophageal epithelial cells via the Sonic hedgehog pathway Front. Cell. Infect. Microbiol. 2022 12 982636 10.3389/fcimb.2022.982636 36262185 PMC9573957 · DOI
  186. [204]Gao S Selective activation of TGFβ signaling by P. gingivalis-mediated upregulation of GARP aggravates esophageal squamous cell carcinoma Am. J. Cancer Res. 2023 13 2013 2029 37293157 PMC10244119
  187. [205]Próchnicki T Latz E Inflammasomes on the crossroads of innate immune recognition and metabolic control Cell Metab. 2017 26 71 93 10.1016/j.cmet.2017.06.018 28683296 · DOI
  188. [206]Wang X Porphyromonas gingivalis promotes Colorectal Carcinoma by activating the Hematopoietic NLRP3 inflammasome Cancer Res. 2021 81 2745 2759 10.1158/0008-5472.CAN-20-3827 34003774 · DOI
  189. [207]Jane SM Ting SB Cunningham JM Epidermal impermeable barriers in mouse and fly Curr. Opin. Genet. Dev. 2005 15 447 453 10.1016/j.gde.2005.05.005 15950458 · DOI
  190. [208]Venkatesan K McManus HR Mello CC Smith TF Hansen U Functional conservation between members of an ancient duplicated transcription factor family, LSF/Grainyhead Nucleic Acids Res. 2003 31 4304 4316 10.1093/nar/gkg644 12888489 PMC169928 · DOI
  191. [209]Liang G Porphyromonas gingivalis promotes the proliferation and migration of esophageal squamous cell carcinoma through the miR-194/GRHL3/PTEN/Akt Axis ACS Infect. Dis. 2020 6 871 881 10.1021/acsinfecdis.0c00007 32298082 · DOI
  192. [210]Liu Y Porphyromonas gingivalis promotes malignancy and chemo-resistance via GSK3β-mediated mitochondrial oxidative phosphorylation in human esophageal squamous cell carcinoma Transl. Oncol. 2023 32 101656 10.1016/j.tranon.2023.101656 36989676 PMC10074990 · DOI
  193. [211]Groeger S Oral squamous carcinoma cells express B7-H1 and B7-DC receptors in vivo Pathol. Oncol. Res.: POR 2017 23 99 110 10.1007/s12253-016-0100-7 27498988 · DOI
  194. [212]Ren J P. gingivalis infection upregulates PD-L1 expression on dendritic cells, suppresses CD8+T-cell responses, and aggravates oral cancer Cancer Immunol. Res. 2023 11 290 305 10.1158/2326-6066.CIR-22-0541 36633576 PMC9975670 · DOI
  195. [213]Li R Clinical significance of porphyromonas gingivalis enriching cancer stem cells by inhibiting programmed cell death Factor 4 in Esophageal squamous cell carcinoma ACS Infect. Dis. 2023 9 1846 1857 10.1021/acsinfecdis.3c00182 37723647 · DOI
  196. [214]Tateda M Streptococcus anginosus in head and neck squamous cell carcinoma: implication in carcinogenesis Int. J. Mol. Med. 2000 6 699 703 11078831
  197. [215]D’Errico G Machado HL Sainz B Jr. A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet Clin. Transl. Med. 2017 6 3 10.1186/s40169-016-0130-5 28050779 PMC5209322 · DOI
  198. [216]Shin YH Revisiting Coley’s Toxins: Immunogenic Cardiolipins from Streptococcus pyogenes J. Am. Chem. Soc. 2023 145 21183 21188 10.1021/jacs.3c07727 37738205 PMC10557101 · DOI
  199. [217]Mougeot JC Haemophilus pittmaniae and Leptotrichia spp. constitute a multi-marker signature in a cohort of human papillomavirus-positive head and neck cancer patients Front. Microbiol. 2021 12 794546 10.3389/fmicb.2021.794546 35116012 PMC8803733 · DOI
  200. [218]Rai AK Dysbiosis of salivary microbiome and cytokines influence oral squamous cell carcinoma through inflammation Arch. Microbiol. 2021 203 137 152 10.1007/s00203-020-02011-w 32783067 · DOI

200 of 259 shown

Cited by

Sorted by citations

Authors
Wang, Z., Sun, W., Hua, R., Wang, Y., Li, Y., & Zhang, H.
Affiliations
  • Anhui Medical University (CN)
  • First Affiliated Hospital of Anhui Medical University (CN)
Corresponding author
  • Li, Yang
  • Zhang, Hengguo
ORCID
Venue
International Journal of Oral Science
Publisher
Springer Science and Business Media LLC
Published
2024-03-13
Volume
16
Issue
1
Pages
24-24
ISSN
  • 1674-2818 (ISSN-L)
  • 2049-3169
DOI
10.1038/s41368-024-00282-3
PMC
PMC10933493
OpenAlex
W4392755968
Cited by
97
References
21
Citations by year
2026: 14 · 2025: 28 · 2024: 55
FWCI
4.34
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Oral Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Anhui Medical University (2022xkfyhz09)
  • National Natural Science Foundation of China (No. 82201026)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
oral bacteria, engineered bacteria, tumor microenvironment, oral microbiota, cancer therapy, oral cancer, biosafety, carcinogenesis
MeSH terms
Bacteria, Humans, Mouth, Neoplasms, Tumor Microenvironment, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review